SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

TEVA’s TEV-408 shows favorable phase II-A celiac results

TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically meaningful gut-architecture protection and inflammation reduction in a phase II-A celiac disease study, with favorable safety and symptom trends. The program will advance to further regulatory discussions.

TEVA

TEV-408, an anti-IL-15 antibody, showed statistically and clinically meaningful protection of gut architecture and a reduction in inflammation in a phase II-A celiac disease study, while safety and symptom trends were favorable. The program will move on to further regulatory discussions and expanded…

Related stories